Vascular Inflammation in Psoriasis - Apremilast

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of Pennsylvania
Study ID
NCT03082729
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast — DRUG
    Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.

Study Details

The purpose of the VIP-A study is to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis.

Key Dates

First listed
Mar 17, 2017
Start date
Apr 24, 2017
Status verified
Oct 2022
Primary completion
Aug 17, 2021
Completion
Aug 17, 2021

Study Design

Enrollment
70 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Apremilast
    Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.

Primary Outcome Measure

Change in Total Vascular Inflammation of the Aorta as Measured by FDG-PET/CT Between Baseline and Week 16. [ Time Frame: After the completion of week 16 visit by all study participants. ]

Locations (7)

FacilityCityStateZIPSite coordinators
University of Southern CaliforniaLos AngelesCalifornia90033-
Derm Associates, P.C.RockvilleMaryland20850-
Buffalo Medical Group, P.C.BuffaloNew York14221-
Oregon Medical Research CenterPortlandOregon97223-
Dermatology and Skin Surgery CenterExtonPennsylvania19341-
The University of PennsylvaniaPhiladelphiaPennsylvania19140-
Center for Clinical StudiesHoustonTexas77004-

Find similar trials in Los Angeles, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of Southern California· Los Angeles, CADerm Associates, P.C.· Rockville, MDBuffalo Medical Group, P.C.· Buffalo, NYOregon Medical Research Center· Portland, ORDermatology and Skin Surgery Center· Exton, PAThe University of Pennsylvania· Philadelphia, PA

Related Studies